TransCode Therapeutics, Inc. Completes Phase 1a Clinical Trial with TTX-MC138
Less than 1 min read
On October 14, 2025, TransCode Therapeutics, Inc. announced the completion of its Phase 1a clinical trial with TTX-MC138.
Key Highlights:
- Primary safety endpoint achieved, enabling Phase 2a trial.
- 44% of patients showed stable disease for over 4 months.
- No significant safety events or dose-limiting toxicities observed.
- Three patients remain on trial with ongoing treatment.
- Positive pharmacodynamic effects support further clinical evaluation.
Original SEC Filing: Transcode Therapeutics, Inc. [ RNAZ ] - 8-K - Oct. 14, 2025
AI-powered summaries may contain inaccuracies. Consider verifying important information with the source.